{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:19:33Z","timestamp":1794680373838,"version":"4.9.1"},"reference-count":152,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"publisher","award":["DS462"],"award-info":[{"award-number":["DS462"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Recent advancements in cancer immunotherapy have made directing the cellular immune response onto cancer cells a promising strategy for the treatment of hematological malignancies. The introduction of monoclonal antibody-based (mAbs) targeted therapy has significantly improved the prognosis for hematological patients. Facing the issues of mAb-based therapies, a novel bispecific antibody (BsAb) format was developed. T-cell engagers (TCEs) are BsAbs, which simultaneously target tumor-associated antigens on tumor cells and CD3 molecules present on T-cells. This mechanism allows for the direct activation of T-cells and their anti-tumor features, ultimately resulting in the lysis of tumor cells. In 2014, the FDA approved blinatumomab, a TCE directed to CD3 and CD19 for treatment of acute lymphoblastic leukemia. Since then, numerous TCEs have been developed, allowing for treating different hematological malignancies such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma and Hodgkin lymphoma. As of November 2023, seven clinically approved TCE therapies are on the market. TCE-based therapies still have their limitations; however, improving the properties of TCEs, as well as combining TCE-based therapies with other forms of treatment, give hope to find the cures for currently terminal diseases. In this paper, we summarized the technical basis of the TCE technology, its application in hematology, and its current issues and prospects.<\/jats:p>","DOI":"10.3390\/cancers16081580","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T03:57:07Z","timestamp":1713758227000},"page":"1580","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["T-Cell Engagers\u2014The Structure and Functional Principle and Application in Hematological Malignancies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9931-3543","authenticated-orcid":false,"given":"Pawe\u0142","family":"Cech","sequence":"first","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Sk\u00f3rka","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dziki","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-4030","authenticated-orcid":false,"given":"Krzysztof","family":"Giannopoulos","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11899-019-00542-8","article-title":"Mechanisms of Resistance to Monoclonal Antibodies (MAbs) in Lymphoid Malignancies","volume":"14","author":"Torka","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of Action of Therapeutic Antibodies for Cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14712598.2019.1604672","article-title":"Treatment of Hematological Malignancies with T Cell Redirected Bispecific Antibodies: Current Status and Future Needs","volume":"19","author":"Foster","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the Major Component of a Peptic Digest of Rabbit Antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a Mixture of Univalent Antibody Fragments of Different Specificity","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity","volume":"256","author":"Milstein","year":"1975","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/305537a0","article-title":"Hybrid Hybridomas and Their Use in Immunohistochemistry","volume":"305","author":"Milstein","year":"1983","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia Coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An Efficient Route to Human Bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pharmthera.2017.12.002","article-title":"Bispecific Antibodies for Cancer Therapy: A Review","volume":"185","author":"Krishnamurthy","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T Cells to Hematological Malignancies with Bispecific Antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1130052","DOI":"10.3389\/fimmu.2023.1130052","article-title":"G Protein-Coupled Receptor 183 Mediates the Sensitization of Burkitt Lymphoma Tumors to CD47 Immune Checkpoint Blockade by Anti-CD20\/PI3K\u03b4i Dual Therapy","volume":"14","author":"Ribeiro","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and Efficacy of a Monovalent Bispecific Pd-1\/Ctla4 Antibody That Enhances Ctla4 Blockade on Pd-1+ Activated t Cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1047610","DOI":"10.3389\/fimmu.2022.1047610","article-title":"PD-1\/LAG-3 Bispecific Antibody Potentiates T Cell Activation and Increases Antitumor Efficacy","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific Antibody Based Therapeutics: Strengths and Challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1126\/science.3925553","article-title":"Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments","volume":"229","author":"Brennan","year":"1985","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering Therapeutic Bispecific Antibodies Using CrossMab Technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4161\/19420862.2015.989013","article-title":"Production of Bispecific Antibodies in \u201cKnobs-into-Holes\u201d Using a Cell-Free Expression System","volume":"7","author":"Xu","year":"2015","journal-title":"MAbs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to Select IgG Subclasses in Developing Anti-Tumor Therapeutic Antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u201cKnobs-into-Holes\u201d Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/protein\/gzy021","article-title":"Variable Heavy\u2013Variable Light Domain and Fab-Arm CrossMabs with Charged Residue Exchanges to Enforce Correct Light Chain Assembly","volume":"31","author":"Regula","year":"2018","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The Use of CrossMAb Technology for the Generation of Bi- and Multispecific Antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V126.23.2998.2998","article-title":"A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys","volume":"126","author":"Vu","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4161\/mabs.26233","article-title":"Production of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange: Scalability from Bench to Large-Scale Manufacturing by Application of Standard Approaches","volume":"5","author":"Gramer","year":"2013","journal-title":"MAbs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific Antibodies and Their Applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The Making of Bispecific Antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow","volume":"14","author":"Fateh","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A Tetravalent Bispecific TandAb (CD19\/CD3), AFM11, Efficiently Recruits T Cells for the Potent Lysis of CD19+ Tumor Cells","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-16-0350","article-title":"Characterization of CD33\/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia","volume":"22","author":"Reusch","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Circosta, P., Elia, A.R., Landra, I., Machiorlatti, R., Todaro, M., Aliberti, S., Brusa, D., Deaglio, S., Chiaretti, S., and Bruna, R. (2018). Tailoring CD19xCD3-DART Exposure Enhances T-Cells to Eradication of B-Cell Neoplasms. Oncoimmunology, 7.","DOI":"10.1080\/2162402X.2017.1341032"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ross, S.L., Sherman, M., McElroy, P.L., Lofgren, J.A., Moody, G., Baeuerle, P.A., Coxon, A., and Arvedson, T. (2017). Bispecific T Cell Engager (BiTE\u00ae) Antibody Constructs Can Mediate Bystander Tumor Cell Killing. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183390"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: Bispecific Antibody Constructs with Unique Anti-Tumor Activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.18632\/oncotarget.27792","article-title":"T-Cell Redirecting Bispecific Antibodies Targeting BCMA for the Treatment of Multiple Myeloma","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"ref_37","first-page":"8007","article-title":"Evaluation of AMG 420, an Anti-BCMA Bispecific T-Cell Engager (BiTE) Immunotherapy, in R\/R Multiple Myeloma (MM) Patients: Updated Results of a First-in-Human (FIH) Phase I Dose Escalation Study","volume":"37","author":"Topp","year":"2019","journal-title":"HemaSphere"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/leu.2012.341","article-title":"T Lymphocytes Can Be Effectively Recruited for Ex Vivo and in Vivo Lysis of AML Blasts by a Novel CD33\/CD3-Bispecific BiTE Antibody Construct","volume":"27","author":"Aigner","year":"2013","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","article-title":"A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE\u00ae) Antibody Construct, in Relapsed\/Refractory Acute Myeloid Leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/1538-7445.AM2017-55","article-title":"Abstract 55: Generation of Half-Life Extended Anti-CD33 BiTE\u00ae Antibody Constructs Compatible with Once-Weekly Dosing","volume":"77","author":"Arvedson","year":"2017","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy across Tumor Types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8795","DOI":"10.1182\/blood-2022-156943","article-title":"Modeling Flotetuzumab-Associated CRS in AML Using InVitro and InVivo Preclinical Models","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1182\/blood-2022-159524","article-title":"A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart\u00ae Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies","volume":"140","author":"Winer","year":"2022","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of Dual Affinity Retargeting Molecules to Achieve Optimal Redirected T-Cell Killing of B-Cell Lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/jmbi.1999.3156","article-title":"Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics","volume":"293","author":"Kipriyanov","year":"1999","journal-title":"J. Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13063-022-06982-7","article-title":"Safety of AFM11 in the Treatment of Patients with B-Cell Malignancies: Findings from Two Phase 1 Studies","volume":"24","author":"Topp","year":"2023","journal-title":"Trials"},{"key":"ref_47","first-page":"2815","article-title":"Generation of a Half-Life Extended Anti-CD19 BiTE\u00ae Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies","volume":"130","author":"Lorenczewski","year":"2017","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (Bispecific T-Cell Engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma: Recommended Dose Safety\/Efficacy Update and Escalation Exposure-Response Analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-Cell Engaging Antibodies for Cancer Therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13543776.2018.1428307","article-title":"Therapeutic Bispecific Antibody Formats: A Patent Applications Review (1994-2017)","volume":"28","author":"Godar","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T Cell Engaging Bispecific Antibody (T-BsAb): From Technology to Therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: A CD19\/CD3 Bispecific T Cell Engager (BiTE) with Unique Anti-Tumor Efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12245","article-title":"Novel Immunotherapies for Hematological Malignancies","volume":"263","author":"Nelson","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive Immunity Maintains Occult Cancer in an Equilibrium State","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1158\/0008-5472.CAN-10-1379","article-title":"Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A Recombinant Bispecific Single-Chain Antibody, CD19 x CD3, Induces Rapid and High Lymphoma-Directed Cytotoxicity by Unstimulated T Lymphocytes","volume":"95","author":"Kufer","year":"2000","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02194785","article-title":"Tumor-Infiltrating Lymphocytes as Antitumor Effector Cells","volume":"5","author":"Whiteside","year":"1992","journal-title":"Biotherapy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/mabs.2.2.11221","article-title":"Catumaxomab: Clinical Development and Future Directions","volume":"2","author":"Linke","year":"2010","journal-title":"MAbs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/0008-5472.CAN-11-2235","article-title":"Immunomonitoring Results of a Phase II\/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)","volume":"72","author":"Schoberth","year":"2012","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s12033-012-9612-x","article-title":"With or without Sugar? (A)Glycosylation of Therapeutic Antibodies","volume":"54","author":"Hristodorov","year":"2013","journal-title":"Mol. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-16-0666","article-title":"MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-Specific Molecule Incorporating Extended Circulating Half-Life for the Treatment of B-Cell Malignancies","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-Cell Engagers: Towards Understanding Variables Influencing the in Vitro Potency and Tumor Selectivity and Their Modulation to Enhance Their Efficacy and Safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Middelburg, J., Kemper, K., Engelberts, P., Labrijn, A.F., Schuurman, J., and Van Hall, T. (2021). Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers, 13.","DOI":"10.3390\/cancers13020287"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA Approval: Blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3109\/10428194.2013.828354","article-title":"Therapeutic Targeting of CD19 in Hematological Malignancies: Past, Present, Future and Beyond","volume":"55","author":"Katz","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/08916934.2014.921810","article-title":"CD19 Differentially Regulates BCR Signalling through the Recruitment of PI3K","volume":"47","author":"Xu","year":"2014","journal-title":"Autoimmunity"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab Maintenance after Allogeneic Hematopoietic Cell Transplantation for B-Lineage Acute Lymphoblastic Leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, Phase 2 Study of Blinatumomab as Second Salvage Therapy in Adults with Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-Term Outcome of Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma Treated with Blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2021-152822","article-title":"A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed \/ Refractory (R\/R) Indolent Non Hodgkin\u2019s Lymphoma (NHL)","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/hon.14_2632","article-title":"A First-In-Human Study Of A Half-Life Extended Cd19-Targeting Bite in Relapsed\/Refractory Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma","volume":"37","author":"Popplewell","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The Regulation and Function of CD20: An \u201cEnigma\u201d of B-Cell Biology and Targeted Therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2005.02720.x","article-title":"Rituxan (Anti-CD20 Antibody)-Induced Translocation of CD20 into Lipid Rafts Is Crucial for Calcium Influx and Apoptosis","volume":"139","author":"Janas","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a Human CD20\u00d7CD3 Bispecific Antibody in Patients with CD20-Positive B-Cell Malignancies (ELM-1): Results from the Relapsed or Refractory Non-Hodgkin Lymphoma Cohort in a Single-Arm, Multicentre, Phase 1 Trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2022-158404","article-title":"Odronextamab in Patients with Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL System: Emerging Functions beyond B Cell Biology and Autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B Cell Maturation Antigen as a Target for Antibody Drug Conjugate Mediated Cytotoxicity in Multiple Myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood.V62.1.124.124","article-title":"Myeloid-Associated Differentiation Antigens on Stem Cells and Their Progeny Identified by Monoclonal Antibodies","volume":"62","author":"Andrews","year":"1983","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4081\/oncol.2012.e8","article-title":"An Overview on the Role of FLT3-Tyrosine Kinase Receptor in Acute Myeloid Leukemia: Biology and Treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 Mutations in Acute Myeloid Leukemia: Therapeutic Paradigm beyond Inhibitor Development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e003882","DOI":"10.1136\/jitc-2021-003882","article-title":"A Novel IgG-Based FLT3xCD3 Bispecific Antibody for the Treatment of AML and B-ALL","volume":"10","author":"Mehta","year":"2022","journal-title":"J. Immunother. cancer"},{"key":"ref_85","first-page":"1","article-title":"Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?","volume":"21","author":"Bourlon","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and Activity of Blinatumomab for Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukaemia: A Multicentre, Single-Arm, Phase 2 Study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 Study of the Bispecific T-Cell Engager (BiTE) Antibody Blinatumomab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient Elimination of Chronic Lymphocytic Leukaemia B Cells by Autologous T Cells with a Bispecific Anti-CD19\/Anti-CD3 Single-Chain Antibody Construct","volume":"17","author":"Gruen","year":"2003","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab Induces Autologous T-Cell Killing of Chronic Lymphocytic Leukemia Cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T Cell-Dependent Bispecific Antibody for the Treatment of B Cell Malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/1060028019833992","article-title":"Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma","volume":"53","author":"Eltantawy","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab Is an Active T Cell\u2013Redirecting Bispecific Antibody against B-Cell Maturation Antigen for Multiple Myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: First Approval","volume":"83","author":"Shirley","year":"2023","journal-title":"Drugs"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Engelberts, P.J., Hiemstra, I.H., de Jong, B., Schuurhuis, D.H., Meesters, J., Beltran Hernandez, I., Oostindie, S.C., Neijssen, J., van den Brink, E.N., and Horbach, G.J. (2020). DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine, 52.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: First Approval","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG Family Member, GPRC5D, Is Associated with Hard-Keratinized Structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G Protein-Coupled Receptor 5D in the Bone Marrow Is Associated with Poor Prognosis in Patients with Multiple Myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Keam, S.J. (2023). Talquetamab: First Approval. Drugs, 83.","DOI":"10.1007\/s40265-023-01945-x"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in Combination with Daratumumab for Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"TPS8065","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","article-title":"MagnetisMM-6: An Open-Label, Multicenter, Randomized Phase 3 Study of Elranatamab + Daratumumab + Lenalidomide (EDR) versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Transplant Ineligible (TI) Patients with Newly Diagnosed Multiple Myeloma (NDMM)","volume":"41","author":"Grosicki","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"TPS8066","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","article-title":"MagnetisMM-7: An Open-Label, Multicenter, Randomized Phase 3 Study of Elranatamab versus Lenalidomide in Post-Transplant Patients with Newly Diagnosed Multiple Myeloma","volume":"41","author":"Grosicki","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of Regulatory T Cells Determines the Outcome of the T-Cell-Engaging Antibody Blinatumomab in Patients with B-Precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2018.36.5_suppl.209","article-title":"A Novel T-Cell Bispecific Antibody Platform for Efficient T-Cell Mediated Killing of Tumor Cells with Minimal Cytokine Release","volume":"36","author":"Rangaswamy","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 Axis Augments Lysis of AML Cells by the CD33\/CD3 BiTE Antibody Construct AMG 330: Reversing a T-Cell-Induced Immune Escape Mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"ref_116","first-page":"e340","article-title":"T-Cell Ligands Modulate the Cytolytic Activity of the CD33\/CD3 BiTE Antibody Construct, AMG 330","volume":"5","author":"Laszlo","year":"2015","journal-title":"Blood Cancer J. 2015 58"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"K\u00f6hnke, T., Krupka, C., Tischer, J., Kn\u00f6sel, T., and Subklewe, M. (2015). Increase of PD-L1 Expressing B-Precursor ALL Cells in a Patient Resistant to the CD19\/CD3-Bispecific T Cell Engager Antibody Blinatumomab. J. Hematol. Oncol., 8.","DOI":"10.1186\/s13045-015-0213-6"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-Cell Responses against CD19+ Pediatric Acute Lymphoblastic Leukemia Mediated by Bispecific T-Cell Engager (BiTE) Are Regulated Contrarily by PD-L1 and CD80\/CD86 on Leukemic Blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ Regulatory T Cells Suppress Tumor Immunity but Are Sensitive to Cyclophosphamide Which Allows Immunotherapy of Established Tumors to Be Curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic Identification and Characterization of Granulocytic Myeloid-Derived Suppressor Cells in Multiple Myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted Therapy with the T-Cell\u2014Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-Intrinsic and -Extrinsic Determinants of Response to Blinatumomab in Adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1182\/blood.V128.22.5196.5196","article-title":"Lineage Switch Under Blinatumomab of a Relapsed Common ALL Co-Expressing Myeloid Markers without MLL Rearrangement","volume":"128","author":"Zoghbi","year":"2016","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine Release Syndrome with Novel Therapeutics for Acute Lymphoblastic Leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic Adverse Events in Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia Treated with Blinatumomab: Management and Mitigating Factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine Release Syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-1947-7-280","article-title":"Treatment Strategy for Reducing the Risk of Rituximab-Induced Cytokine Release Syndrome in Patients with Intravascular Large B-Cell Lymphoma: A Case Report and Review of the Literature","volume":"7","author":"Makino","year":"2013","journal-title":"J. Med. Case Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000337577","article-title":"Rituximab and Cytokine Release Syndrome","volume":"5","author":"Kulkarni","year":"2012","journal-title":"Case Rep. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T Cell-Induced Cytokine Release Syndrome Is Mediated by Macrophages and Abated by IL-1 Blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A Multicenter Phase 1 Study of Solitomab (MT110, AMG 110), a Bispecific EpCAM\/CD3 T-Cell Engager (BiTE\u00ae) Antibody Construct, in Patients with Refractory Solid Tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The Effect of Dexamethasone on Polyclonal T Cell Activation and Redirected Target Cell Lysis as Induced by a CD19\/CD3-Bispecific Single-Chain Antibody Construct","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but Not Dexamethasone, Prevents CRS without Affecting Antitumor Activity of Bispecific Antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","article-title":"Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events","volume":"80","author":"Klinger","year":"2020","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune Effector Cell\u2013Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro. Oncol."},{"key":"ref_139","first-page":"86","article-title":"Trispecific Antibodies Enhance the Therapeutic Efficacy of Tumor-Directed T Cells through T Cell Receptor Co-Stimulation","volume":"1","author":"Wu","year":"2019","journal-title":"Nat. Cancer 2019 11"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood.V106.11.4690.4690","article-title":"Diagnostic Approach to CD5+\/CD23+ Leukemic Non-Hodgkin Lymphomas Lacking Lymphnode Histopathology","volume":"106","author":"Anaclerico","year":"2005","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T Cells Secreting BiTEs Circumvent Antigen Escape without Detectable Toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Guo, Z.S., Lotze, M.T., Zhu, Z., Storkus, W.J., and Song, X.T. (2020). Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8070204"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2019-129657","article-title":"Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)","volume":"134","author":"Kantarjian","year":"2019","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1182\/blood-2019-132048","article-title":"Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia","volume":"134","author":"Fleming","year":"2019","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-138565","article-title":"Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study","volume":"136","author":"Short","year":"2020","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2019-121708","article-title":"Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma","volume":"134","author":"Katz","year":"2019","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","article-title":"Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed\/Refractory (R\/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study","volume":"132","author":"Webster","year":"2018","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1182\/blood-2022-170279","article-title":"Interim Results of a Phase 1\/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed\/Refractory (r\/r) ALL","volume":"140","author":"Sandhu","year":"2022","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1002\/acg2.50","article-title":"Case Report: Impact of BITE on CAR-T Cell Expansion","volume":"2","author":"Shalabi","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Scott, E.M., Duffy, M.R., Freedman, J.D., Fisher, K.D., and Seymour, L.W. (2018). Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses. Macromol. Biosci., 18.","DOI":"10.1002\/mabi.201700187"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"295393","DOI":"10.3389\/fonc.2017.00202","article-title":"Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies","volume":"7","author":"Jhawar","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-17-2651","article-title":"Targeted Bite Expression by an Oncolytic Vector Augments Therapeutic Efficacy against Solid Tumors","volume":"24","author":"Speck","year":"2018","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1580\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:31:33Z","timestamp":1760106693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":152,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081580"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081580","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]}}}